Related Experiment Video
Updated: May 31, 2025

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Hereditary angioedema: Patient health care experiences within underrepresented racial and ethnic groups in the United
Timothy Craig1, Alan P Baptist2, John Anderson3
1Allergy, Asthma and Immunology, Departments of Medicine, Pediatrics, and Biomedical Sciences, Director ACARE International Hereditary Angioedema Resource Center, Penn State University, Hershey, Pennsylvania; Vinmec International Hospital, Times City, Hanoi, Vietnam.
Background:
Hereditary angioedema (HAE) is a rare disorder in which unpredictable angioedema attacks significantly affect patient quality of life. Information on patient experiences and perspectives of HAE management within underrepresented racial and ethnic groups is limited.
Objective:
To gain insight into the experiences and perspectives of medical care and treatment of HAE among underrepresented racial and ethnic groups in the United States.
Methods:
Adult patients diagnosed with having HAE who self-identified as members of an underrepresented racial and/or ethnic group were recruited to participate in a noninterventional, observational, web-based patient survey. The questionnaire included questions on medical history, current and past treatments, resource utilization, and perceived disease severity. The patient-perceived impact of HAE on the quality of life was also measured.
Results:
Overall, 139 patients participated in the survey; 33.1% were identified solely as "African American or Black" and 30.2% solely as "Hispanic, Latin American, Latin, or Latine, or Latinx." Before the diagnosis, 12.3% of the patients were satisfied with their HAE-related health care experiences. Many participants experienced difficulties obtaining an HAE diagnosis. Barriers to treatment include insufficient provider knowledge of HAE and misdiagnoses. More than 90% of the patients were satisfied with their care; however, patients reported 6 HAE attacks (median) in the past year and only 10.4% of the patients were attack free. Furthermore, 38.1% found it difficult or very difficult to cover the monthly out-of-pocket costs for HAE-related treatments and 24.6% felt that their provider sometimes/rarely/never considered their individual background when making medical decisions.
Conclusion:
Barriers to HAE diagnosis and effective treatment persist among US patients from underrepresented racial and ethnic groups.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Hormonal Regulation
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Allergic Reactions
Antihypertensive Drugs: Direct Renin Inhibitors

